UK markets closed

Sanofi (SAN.PA)

Paris - Paris Delayed price. Currency in EUR
Add to watchlist
86.48-1.71 (-1.94%)
At close: 05:37PM CET
Full screen
Previous close88.19
Open87.83
Bid0.00 x 0
Ask0.00 x 0
Day's range85.18 - 88.13
52-week range76.45 - 106.66
Volume4,271,490
Avg. volume1,840,556
Market cap109.613B
Beta (5Y monthly)0.46
PE ratio (TTM)16.96
EPS (TTM)5.10
Earnings date28 Oct 2022
Forward dividend & yield3.33 (3.78%)
Ex-dividend date06 May 2022
1y target est103.79
  • Bloomberg

    Horizon Therapeutics in Separate Sale Talks With Amgen, Sanofi, J&J

    (Bloomberg) -- Horizon Therapeutics Plc rose by the most in more than three years after the drug developer disclosed it’s in talks with a trio of potential suitors about a possible sale of the company.Most Read from BloombergScientists Revive 48,500-Year-Old ‘Zombie Virus’ Buried in IceNYC Becomes One Billionaire Family’s Haven From China Property CrashThese Are the Best and Worst Cities for Expats to Live and Work InBanks Stuck With $42 Billion Debt Seize Chance to Offload ItAmgen Inc., Johnson

  • Motley Fool

    Why Horizon Therapeutics Stock Is Skyrocketing Today

    Shares of Horizon Therapeutics (NASDAQ: HZNP) were skyrocketing 27.2% higher as of 10:48 a.m. ET on Wednesday. The big jump came after the company announced Thursday evening that it's in discussions with Amgen (NASDAQ: AMGN), Johnson & Johnson (NYSE: JNJ) subsidiary Janssen, and Sanofi (NASDAQ: SNY) about potentially being acquired. There were two words in Horizon's press release that investors should note: "highly preliminary."

  • Globe Newswire

    Press Release: Acoziborole: Investigational single-dose oral treatment raises hope for elimination of sleeping sickness in Africa

    Acoziborole: Investigational single-dose oral treatment raises hope for elimination of sleeping sickness in Africa Positive Phase II/III study results support acoziborole’s potential in treatment for deadly disease Geneva, Kinshasa, Paris – November 30, 2022. The Drugs for Neglected Diseases initiative (DNDi) and Sanofi announce treatment success rates of up to 95% from a Phase II/III study investigating the safety and efficacy of single-dose acoziborole, a potentially transformative investigati